Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Direct thrombin inhibitors.

Jeffrey I Weitz1, Mark Crowther

  • 1McMaster University and Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3. jweitz@thrombosis.hhscr.org

Thrombosis Research
|October 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

Direct thrombin inhibitors offer improved antithrombotic therapy over heparin by providing predictable responses and inhibiting fibrin-bound thrombin. This review examines their clinical data and future role in anticoagulation.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Thrombin is a key enzyme in thrombosis, making it a primary target for antithrombotic therapies.
  • Heparin, a traditional anticoagulant, has limitations including unpredictable responses and inability to inhibit fibrin-bound thrombin.

Purpose of the Study:

  • To review clinical trial data for direct thrombin inhibitors (DTIs).
  • To discuss the role of DTIs in light of emerging anticoagulant therapies.

Main Methods:

  • Review of clinical trial data for parenteral and oral direct thrombin inhibitors.
  • Comparative analysis of DTIs versus heparin and other anticoagulants.

Main Results:

  • Direct thrombin inhibitors demonstrate predictable anticoagulant effects, unaffected by platelet factor 4.

Related Experiment Videos

  • DTIs effectively inhibit fibrin-bound thrombin, a critical factor in thrombus progression.
  • Parenteral DTIs like hirudin, bivalirudin, and argatroban are approved; oral agents are under investigation.

    • Conclusions:

    • Direct thrombin inhibitors represent an advancement over heparin, addressing its limitations.
    • DTIs offer a valuable therapeutic option for thrombosis management.
    • The ongoing development of oral DTIs promises expanded therapeutic applications.